C-Type Natriuretic Peptide (CNP) (1-22), human

Name: C-Type Natriuretic Peptide (CNP) (1-22), human
Brand: MedChemExpress
SKU: HY-P1237
Rating: 4.5 (1 reviews)

Cat. No.: HY-P1237 Purity: 99.41%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

C-Type Natriuretic Peptide (CNP) (1-22), human, a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

C-Type Natriuretic Peptide (CNP) (1-22), human Chemical Structure

CAS No. : 127869-51-6

Size	Price	Stock	Quantity
500 μg	USD 100	In-stock	Estimated Time of Arrival: December 31
1 mg	USD 150	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 600	In-stock	Estimated Time of Arrival: December 31
10 mg		Get quote
50 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of C-Type Natriuretic Peptide (CNP) (1-22), human:

C-Type Natriuretic Peptide (CNP) (1-22), human TFA Get quote

1 Publications Citing Use of MCE C-Type Natriuretic Peptide (CNP) (1-22), human

•Acta Biomater. 2022 Aug 21;S1742-7061(22)00506-2. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

NPR-B^[1]

In Vitro

C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) (0.01, 0.1, 1, 10, 100, 1000 nM) increases cGMP production in CHO cells expressing human NPR-B in a concentration-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PK parameters of CNP immunoreactivity after a single intravenous administration of C-Type Natriuretic Peptide (CNP) (1-22), human^[1]:

Dose (nM/kg)	AUC_0-∞ (pM·min/mL)	MRT_0-∞ (min)	T_1/2 (min)	CL_tot (mL/min/kg)	Vd_ss (mL/kg)
20	320±54	1.02±0.18	1.42±0.45	63.9±11.9	64.2±5.1

PK parameters of CNP immunoreactivity after a single subcutaneous administration of C-Type Natriuretic Peptide (CNP) (1-22), human^[1]:

Dose (nM/kg)	Cmax (pM/mL)	Tmax (min)	AUC_0-∞ (pM·min/mL)	MRT_0-∞ (min)	T_1/2 (min)	BA (%)
50	9.02±3.74	5.0±0.0	152±73	13.9±3.4	10.0±5.0	19±9

Each value represents the mean±SD of 3 rats. MRT=mean residence time, CL_tot=total clearance, T_1/2=half-life period, BA=bioavailability.
C-Type Natriuretic Peptide (CNP) (1-22) ( i.c.v.) in a dose of 2 nM induces an increase in the severity of picrotoxin-kindled convulsions 24 and 48 hrs after application of the peptide^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

2197.60

Formula

C₉₃H₁₅₇N₂₇O₂₈S₃

CAS No.

127869-51-6

Appearance

Solid

Color

White to off-white

Sequence

Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys (Disulfide bridge: Cys6-Cys22)

Sequence Shortening

GLSKGCFGLKLDRIGSMSGLGC (Disulfide bridge: Cys6-Cys22)

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : 50 mg/mL (22.75 mM; adjust pH to 3 with 0.5%CH3COOH)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.4550 mL	2.2752 mL	4.5504 mL
5 mM	0.0910 mL	0.4550 mL	0.9101 mL
10 mM	0.0455 mL	0.2275 mL	0.4550 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.41%

Select Batch:

Data Sheet (276 KB) SDS (252 KB)

COA (242 KB) LCMS (261 KB)

Handling Instructions (2659 KB)

References

[1]. Morozumi N, et al. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14(2):e0212680. [Content Brief]

[2]. Buckley MG, et al. Circulating C-type natriuretic peptide is increased in orthotopic cardiac transplant recipients and associated with cardiac allograft vasculopathy. Clin Sci (Lond). 2000 Nov;99(5):467-72. [Content Brief]

[3]. Mazarati AM, et al. ANP(1-28), BNP(1-32) and CNP(1-22) increase the severity of picrotoxin-kindled seizure syndrome in rats. Life Sci. 1993;52(3):PL19-24. [Content Brief]

Animal Administration

Rats^[3]

Rats are preliminarily kindled with picrotoxin and convulsion is monitored. Rats then receive I.c.v. administration of C-Type Natriuretic Peptide (CNP) (1-22) (0.2, 1 or 2 nM in 2 mcl of 0.9% NaCI) under conditions of free behavior. Control animals receive an equal volume of saline. Within 10 min after the injections of the peptides, picrotoxin (1.5 mg/kg) is administered i.p. and the convulsion severity is evaluated as mentioned above^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Morozumi N, et al. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14(2):e0212680. [Content Brief]

[2]. Buckley MG, et al. Circulating C-type natriuretic peptide is increased in orthotopic cardiac transplant recipients and associated with cardiac allograft vasculopathy. Clin Sci (Lond). 2000 Nov;99(5):467-72. [Content Brief]

[3]. Mazarati AM, et al. ANP(1-28), BNP(1-32) and CNP(1-22) increase the severity of picrotoxin-kindled seizure syndrome in rats. Life Sci. 1993;52(3):PL19-24. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O	1 mM	0.4550 mL	2.2752 mL	4.5504 mL	11.3760 mL
	5 mM	0.0910 mL	0.4550 mL	0.9101 mL	2.2752 mL
	10 mM	0.0455 mL	0.2275 mL	0.4550 mL	1.1376 mL
	15 mM	0.0303 mL	0.1517 mL	0.3034 mL	0.7584 mL
	20 mM	0.0228 mL	0.1138 mL	0.2275 mL	0.5688 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.